Clinical trial
Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
NCT05508464 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- October 16, 2023
- Completion date
- January 1, 2034
- Enrollment
- 138 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic cancer